Degenerative polyarthritis
|
0.130 |
Biomarker
|
disease |
BEFREE |
MCF2L is involved in neurotrophin mediated regulation of cell motility in the peripheral nervous system, and thus potentially implicated in nociception in OA.
|
22178404 |
2012 |
Degenerative polyarthritis
|
0.130 |
Biomarker
|
disease |
BEFREE |
MCF2L regulates a nerve growth factor (NGF), and treatment with a humanized monoclonal antibody against NGF is associated with reduction in pain and improvement in function for knee OA patients.
|
21871595 |
2011 |
Degenerative polyarthritis
|
0.130 |
GeneticVariation
|
disease |
BEFREE |
There are no non-synonymous SNPs that correlate with this association signal and we therefore set out to assess whether its effect on OA susceptibility is mediated by alteration of MCF2L expression.
|
26584642 |
2015 |
Cardiovascular Diseases
|
0.110 |
GeneticVariation
|
group |
BEFREE |
In conclusion, a rare functional variant in MCF2L, leading to impaired DH function, was identified in a small pedigree with premature CVD.
|
25898923 |
2016 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
As the course of disease duration as well as the age at operation seem to correlate with DBS outcome in patients with dystonia, DBS at an early stage of development might be beneficial for some of these patients.
|
27289260 |
2017 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
GPi-DBS should be considered to ameliorate the invalidating dystonia in these patients.
|
27862284 |
2017 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The present study confirms the effectiveness of pallidal DBS in a new family with hereditary primary segmental and generalized dystonia.
|
19890997 |
2009 |
Dystonia
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Some of the rarer types of dystonia that have also been treated with DBS are also described.
|
20083014 |
2009 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
DBS effects on dystonia severity were variable but overall marginally effective, with a mean improvement of 7.9% (p = 0.39) at 1-year follow-up and 16.7% (p = 0.46) at last follow-up (mean 47.3 ± 19.9 months after surgery).
|
27743838 |
2017 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
DBS has been trialed to treat related movement disorders, particularly dystonia.
|
30633810 |
2019 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Interestingly, DBS for PD can cause dystonia such as blepharospasm and bilateral pallidal DBS for dystonia can result in features of parkinsonism.
|
31078682 |
2019 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Fifty-four subjects with dystonia and DBS for more than 5 years were contacted via social media and were offered to complete a quality-of-life survey comparing current-day life and life prior to DBS.
|
30153389 |
2018 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Pallidal deep-brain stimulation of the internal globus pallidus (GPi-DBS) is an effective treatment for dystonia.
|
30623266 |
2019 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
To assess safety and tolerability of square biphasic DBS in dystonia patients.
|
28195407 |
2017 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We aimed to assess whether the thalamic ventral intermediate nucleus (Vim) might be an alternative DBS target in dystonia-choreoathetosis.
|
30718219 |
2019 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Peak low frequency IMC functioned as biomarker for GPi-DBS efficacy, and partly correlated with dystonia severity.
|
31207566 |
2019 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
To objectively investigate the impact of GPi-DBS on patients with dystonia on speech fluency, intelligibility, and key aspects of hyperkinetic and hypokinetic dysarthria.
|
29576500 |
2019 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
All these results support the multilevel impact of effective DBS on the motor networks in dystonia and suggest potential biomarkers of responsiveness to this treatment.
|
30464181 |
2018 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
There was a significant improvement of dystonia with GPi-DBS (69 % improvement in Burke-Fahn-Marsden score, p < 0.0001).
|
24178706 |
2014 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Clinically, no generalization of dystonia was observed after onset and DBS lead to an excellent motor outcome in two cases.
|
26725140 |
2016 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
GPi DBS is an effective and safe treatment in most patients with dystonia.
|
28972096 |
2017 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Our results showed that bilateral GPi DBS in craniocervical dystonia is effective and safe.
|
29246604 |
2017 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We here investigated causes of insufficient response to GPi-DBS in isolated dystonia in a cross-sectional study.
|
28690015 |
2017 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Pallidal DBS for dystonia in the age of personalized medicine.
|
28964627 |
2017 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
This study shows the benefits of pallidal DBS for the dystonia of PKAN patients.
|
15852393 |
2005 |